Evidence map›Paper›PMID 28794957›Full record

ArticlePreventive medicine reports2017

Prevalence of metabolic syndrome and metabolic syndrome components in young adults: A pooled analysis.

Paul B Nolan, Graeme Carrick-Ranson, James W Stinear, Stacey A Reading, Lance C Dalleck

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Preventive medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05956886 (Artificial Intelligence Sleep Chatbot in Emerging Black/African American Adults With Cardiometabolic Risk Factors), which is not on this map. Cited by 148 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05956886 nacompletednot on this mapstarted 2023, after this paper: background citation

Artificial Intelligence Sleep Chatbot in Emerging Black/African American Adults With Cardiometabolic Risk Factors: a Feasibility Study

TypeinterventionalSponsorUniversity of DelawareRan2023 to 2025Enrolled26ConditionsSleep Deprivation, Insomnia, Metabolic SyndromeArmssleep chatbot
3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. ADHD and metabolic syndrome: behavioral and weight-related pathways to cardiovascular risk.European archives of psychiatry and clinical neuroscience · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Trends in the prevalence of metabolic syndrome among Jordanian adults following COVID-19.Therapeutic advances in endocrinology and metabolism · 2026
    Article

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paul B NolanDepartment of Exercise Sciences, Building 731 Tamaki Innovation Campus, The University of Auckland, 261 Morrin Road, St Johns, Auckland, New Zealand.
Graeme Carrick-RansonDepartment of Exercise Sciences, Building 731 Tamaki Innovation Campus, The University of Auckland, 261 Morrin Road, St Johns, Auckland, New Zealand.
James W StinearDepartment of Exercise Sciences, Building 731 Tamaki Innovation Campus, The University of Auckland, 261 Morrin Road, St Johns, Auckland, New Zealand.
Stacey A ReadingDepartment of Exercise Sciences, Building 731 Tamaki Innovation Campus, The University of Auckland, 261 Morrin Road, St Johns, Auckland, New Zealand.
Lance C DalleckRecreation, Exercise and Sport Science Department, Western State Colorado University, Wright Gym 209, 600 North Adams St, Gunnison, CO 81231, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome (MetSyn) represents a clustering of different metabolic abnormalities. MetSyn prevalence is present in approximately 25% of all adults with increased prevalence in advanced ages. The presence of one component of MetSyn increases the risk of developing MetSyn later in life and likely represents a high lifetime burden of cardiovascular disease risk. Therefore we pooled data from multiple studies to establish the prevalence of MetSyn and MetSyn component prevalence across a broad range of ethnicities. PubMed, SCOPUS and Medline databases were searched to find papers presenting MetSyn and MetSyn component data for 18-30 year olds who were apparently healthy, free of disease, and MetSyn was assessed using either the harmonized, National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII), American Heart Association/National Heart, Blood and Lung Institute (AHA/NHBLI), or International Diabetes Federation (IDF) definitions of MetSyn. After reviewing returned articles, 26,609 participants' data from 34 studies were included in the analysis and the data were pooled. MetSyn was present in 4.8-7% of young adults. Atherogenic dyslipidaemia defined as low high density lipoprotein (HDL) cholesterol was the most prevalent MetSyn component (26.9-41.2%), followed by elevated blood pressure (16.6-26.6%), abdominal obesity (6.8-23.6%), atherogenic dyslipidaemia defined as raised triglycerides (8.6-15.6%), and raised fasting glucose (2.8-15.4%). These findings highlight that MetSyn is prevalent in young adults. Establishing the reason why low HDL is the most prevalent component may represent an important step in promoting primary prevention of MetSyn and reducing the incidence of subsequent clinical disease.

Identifiers

PMID28794957
PMCPMC5540707

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.